Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Chengdu Easton Biopharmaceuticals Co's
Operating Income
for the
three
months ended in Mar. 2026 was ¥41 Mil. Chengdu Easton Biopharmaceuticals Co's Interest Expense for the
three
months ended in Mar. 2026 was ¥-1 Mil.
Chengdu Easton Biopharmaceuticals Co's interest coverage for the quarter that ended in Mar. 2026 was 70.44.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Chengdu Easton Biopharmaceuticals Co Ltd has enough cash to cover all of its debt. Its financial situation is stable.
SHSE:688513'
s Interest Coverage Range Over the Past 10 Years
Min: 60.18 Med: 403.11 Max: No Debt
Current: 99.68
SHSE:688513's Interest Coverage is ranked worse than 51.33% of 376
companies
in the Biotechnology industry
Industry Median: 110.86
vs SHSE:688513: 99.68
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Chengdu Easton Biopharmaceuticals Co Interest Coverage Related Terms
Chengdu Easton Biopharmaceuticals Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Chengdu Easton Biopharmaceuticals Co Interest Coverage Chart
SHSE:688513 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's Interest Coverage falls into.
Chengdu Easton Biopharmaceuticals Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a Interest Coverage of 70.44 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. This is 83% below median its historical median of 403.11. Over the past decade, Chengdu Easton Biopharmaceuticals Co's Interest Coverage has ranged from 60.18 to 10,000.00. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #193 out of 376 companies in the Biotechnology industry, placing it in the top 51.3%.
Is Chengdu Easton Biopharmaceuticals Co's Interest Coverage too high?
Chengdu Easton Biopharmaceuticals Co's current Interest Coverage of 70.44 is 83% below median its 10-year median of 403.11. Over the past 10 years, this metric has ranged from a low of 60.18 to a high of 10,000.00. The Biotechnology industry median Interest Coverage is 110.86. Chengdu Easton Biopharmaceuticals Co's value of 70.44 is 36.5% below this industry median. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #193 out of 376 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #193 out of 376 companies for Interest Coverage. This places Chengdu Easton Biopharmaceuticals Co in the lower half of its industry. The industry median Interest Coverage is 110.86. Chengdu Easton Biopharmaceuticals Co's value of 70.44 is 36.5% below this benchmark. Historically, Chengdu Easton Biopharmaceuticals Co's own Interest Coverage has ranged from 60.18 to 10,000.00 over the past decade. While the company's 10-year median is 403.11 vs. the industry median of 110.86, Chengdu Easton Biopharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 110.86, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengdu Easton Biopharmaceuticals Co's current Interest Coverage of 70.44 is 36.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 110.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengdu Easton Biopharmaceuticals Co's current Interest Coverage is 70.44, which is 83% below median its own 10-year median of 403.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥47.90, compared to a current price of ¥55.10 — trading 15% above its estimated fair value. The current Interest Coverage is 70.44, which is 83% below median its 10-year median of 403.11 and 36.5% below the Biotechnology industry median of 110.86. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current Interest Coverage is 70.44 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥55.10 is trading 15% above its estimated GF Value™ of ¥47.90.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Modestly Overvalued.
Key valuation signals for SHSE:688513:
Interest Coverage: 70.44 (83% below median its 10-year median of 403.11)
GF Value™: ¥47.90 vs. price of ¥55.10 (15% above fair value)
Industry Position: 36.5% below the Biotechnology median (#193 of 376)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Business Description
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
95GF Score
Get the complete analysis for SHSE:688513
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
